MétaCan
Menu
Back to cohort
Record W4401207438 · doi:10.1093/jnci/djae179

NCI workshop on ctDNA in cancer treatment and clinical care

2024· article· en· W4401207438 on OpenAlexfundno aff
Brian S. Sorg, Jung S. Byun, V. Anne Westbrook, James V. Tricoli, James H. Doroshow, Lyndsay N. Harris

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer Genomics and Diagnostics
Canadian institutionsnot available
FundersUniversity of Colorado School of Medicine, Anschutz Medical CampusSidney Kimmel Comprehensive Cancer CenterMorsani College of MedicineUniversity of Texas MD Anderson Cancer CenterChildren's Hospital Los AngelesWeill Cornell Medical CollegeNational Cancer InstituteYale UniversityUniversity of TorontoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel HillUniversity of California, Los AngelesJohns Hopkins UniversityMemorial Sloan-Kettering Cancer CenterOhio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteFrederick National Laboratory for Cancer ResearchFoundation MedicineWashington University in St. LouisMount Sinai Health SystemGenentechUniversity of South FloridaMassachusetts General HospitalNational Institutes of HealthOhio State UniversitySchool of Medicine and Public Health, University of Wisconsin-Madison
KeywordsCancerMedicineOncologyInternal medicine

Abstract

fetched live from OpenAlex

Detection of cell-free circulating tumor DNA (ctDNA) from solid tumors is a fast-evolving field with significant potential for improving patient treatment outcomes. The spectrum of applications for ctDNA assays is broad and includes very diverse intended uses that will require different strategies to demonstrate utility. On September 14-15, 2023, the National Cancer Institute held an in-person workshop in Rockville, MD titled "ctDNA in Cancer Treatment and Clinical Care." The goal of the workshop was to examine what is currently known and what needs to be determined for various ctDNA liquid biopsy use cases related to treatment and management of patients with solid tumors and to explore how the community can best assess the value of ctDNA assays and technology. Additionally, new approaches were presented that may show promise in the future. The information exchanged in this workshop will provide the community with a better understanding of this field and its potential to affect and benefit decision-making in the treatment of patients with solid tumors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.020
metaresearch head score (Gemma)0.022
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.021
Threshold uncertainty score0.105

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0200.022
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0030.002
Scholarly communication0.0060.004
Open science0.0030.009
Research integrity0.0070.017
Insufficient payload (model declined to judge)0.0170.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.061
GPT teacher head0.405
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicCancer Genomics and DiagnosticsFrench-language works237,207